CALGARY, AB, Jan. 12, 2021 /CNW/ - Nanalysis Scientific
Corp. ("Nanalysis"),(TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1),
through its subsidiary RS2D S.A.S. ("RS2D"), is pleased to announce
that it has signed multi-million dollar OEM and licensing deal with
a European corporation.
Rémy Schimpf, Senior VP Sales states "The deal includes
an initial payment of roughly $1
million, and a further $2
million in milestone payments over the next three years. In
addition, there is the strong potential for revenue through OEM
sales in subsequent years an order of magnitude larger. Nanalysis
retains the ownership of intellectual property and has ingredient
branding rights. Although this partner cannot be named at this time
for competition reasons, the partner has tremendous experience and
a successful track record in commercial magnetic resonance
systems.
"This partnership includes our Cameleon4 electronics technology
platform along with our next gen application software, specifically
developed for areas such as molecular imaging, MRI physics, and
virology. The Cameleon4 is also used in our benchtop NMR,
high-field NMR, and MRI products, Our OEM licensing partner will
combine our electronics and software technologies with several
other hardware and software modules to produce a novel, integrated
solution for new and existing magnetic resonance life science
markets globally."
Sean Krakiwsky, founder
and CEO of Nanalysis Scientific adds, "We continue to leverage the
technology we acquired to generate short term revenue, medium term
market opportunities, and achieve our long-term vision. We are
working with quality partners who have a proven track record and
complementary visions for the future of MRI and NMR.
"MRI and NMR machines should not be large, cumbersome, and cost
prohibitive. They should not consume massive amounts of expensive
liquid helium nor require a special room with re-enforced floors.
These devices need to be more accessible and should not run on
cryptic software that only PhD experts can use. We share a vision
with our partners, where MRI and NMR devices are AI-driven,
cryogen-free solutions with software intuitive enough to provide
the simplicity users want, and yet still able to solve highly
complex problems. All of this should be available at affordable
prices. Our vision for NMR and MRI is like that of computers: We
see them evolving from large immobile machines, requiring
specialized operators, towards small devices that sit on a desktop
or in a mobile lab, or wherever the point of need happens to be,
and access data on the cloud to provide optimal, real-time
solutions.
"This partnership is another example of our company leveraging
the commonalities between MRI and NMR. I am incredibly proud of our
team in Strasbourg, which is
leading this area of innovation for our company."
About Nanalysis Scientific Corp. (TSXV: NSCI,
OTCQX: NSCIF, FRA:1N1)
Nanalysis trades on the TSX Venture Exchange (TSXV) in
Canada with ticker symbol 'NSCI',
Over the Counter (OTC) in the United
States under the ticker symbol 'NSCIF', and on the Frankfurt
Exchange (FRA) under the symbol '1N1'.
Nanalysis is an international business focused on capitalizing
its proprietary technologies in nuclear magnetic resonance (NMR)
that go into NMR spectrometers and magnetic resonance imaging
(MRI). Nanalysis operates out of two subsidiaries, Nanalysis Corp.
and RS2D S.A.S. (RS2D).
Nanalysis Corp. is an industry leader in developing and
manufacturing compact NMR spectrometers for laboratory and
industrial markets. Its cutting edge 60 and 100 MHz spectrometers
require no liquid helium or other cryogens. Its spectrometers are
used by chemical professionals spanning industries, including, but
not limited to, oil and gas, chemical mining, pharmaceutical, and
biotechnology.
Through its European subsidiary RS2D, the Company electronic
boards and software used to drive MRI equipment in pre-clinical
configurations and are being incorporated into next-gen MRI
systems.
To sign up for updates relating to Nanalysis, please complete
the online form found HERE.
Notice regarding Forward Looking Statements and Legal
Disclaimer
This news release contains certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "anticipates", "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed", "positioned" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Nanalysis Scientific Corp.